Prodrug of fluorine-containing amino acid
AssigneeTaisho Pharmaceutical Co., Ltd.
InventorsTakashi Hashihayata, Norikazu Otake, Naoki Miyakoshi, Kazunari Sakagami
Life of this patent
Estimating the term…
Loading patent…
AssigneeTaisho Pharmaceutical Co., Ltd.
InventorsTakashi Hashihayata, Norikazu Otake, Naoki Miyakoshi, Kazunari Sakagami
Estimating the term…
Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases.
A compound represented by formula (I):
Dependencies are inferred from the claim text.